drugset
drugset / Trial / NCT05550337

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

NCT05550337 ↗

Phase 3 Completed 807 enrolled Teva Pharmaceuticals USA Teva Pharmaceuticals, Inc. · collab
RandomizedParallel-groupQuadruple-blindOther

Summary

To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.

Timeline

Start
2022-09-19
Primary completion
2023-05-09
Completion
2023-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Trifarotene Small molecule 0.005 % Topical

Indications

acne